The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo

Journal of Clinical Investigation

Volumn 95, Issue 4, 1995, Pages 1773-1781

  Warshawsky, Ilka ^a,c   Bu, Guojun ^a   Mast, Alan ^a   Saffitz, Jeffrey E ^b   Broze Jr , George J ^a   Schwartz, Alan L ^a  

^a Jewish Hospital ^*

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

binding; carboxy terminus; clearance; tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; IODINE 125; LOW DENSITY LIPOPROTEIN RECEPTOR; PLASMA PROTEIN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BLOOD CLOTTING; CELL INTERACTION; FEMALE; HALF LIFE TIME; HEPATOMA CELL; INTERNALIZATION; KIDNEY PROXIMAL TUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; RAT; TISSUE DISTRIBUTION;

EID: 0028969172     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI117855     Document Type: Article

References (34)

1. Rapaport, S. I. 1989. Inhibition of Factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a Factor Xa-dependent inhibitory mechanism. Blood. 73:359-365.
2. Broze, G. J., Jr. 1992. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin. Hematol. 29:159-169.
3. Schneider, C. L. 1947. The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am. J. Physiol. 149:123-129.
4. Thomas, L. 1947. Studies on the intravascular thromboplastin effect of tissue suspensions in mice. II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull. Johns Hopkins Hosp. 81:26-42.
5. Broze, G. J., Jr., L. A. Warren, T. J. Girard, and J. P. Miletich. 1987. Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatoma) cells using bovine Factor Xa affinity chromatography. Thromb. Res. 48:253-259.
6. Broze, G. J., Jr., and J. P. Miletich. 1987. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc. Natl. Acad. Sci. USA. 84:1886-1890.
7. Novotny, W. F., T. J. Girard, J. P. Miletich, and G. J. Broze, Jr. 1989. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J. Biol. Chem. 264:18832-18837.
8. Novotny, W. F., M. Palmier, T.-C. Wun, G. J. Broze, Jr., and J. P. Miletich. 1991. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 78:394-400.
9. Wun, T.-C., K. K. Kretzmer, T. J. Girard, J. P. Miletich, and G. J. Broze, Jr. 1988. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J. Biol. Chem. 263:6001-6004.
10. Broze, G. J., Jr., L. A. Warren, W. F. Novotny, D. A. Higuchi, T. J. Girard, and J. P. Miletich. 1988. The lipoprotein-associated coagulation inhibitor which inhibits the Factor VII-tissue factor complex, also inhibits Factor Xa: insight into its possible mechanism of action. Blood. 71:335-343.
11. Girard, T. J., L. A. Warren, W. F. Novotny, K. M. Likert, S. G. Brown, J. P. Miletich, and G. J. Broze, Jr. 1989. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (Lond.). 338:518-520.
12. Broze, G. J., Jr., G. W. Lange, K. L. Duffin, and L. MacPhail. 1994. Heterogeneity of plasma tissue factor pathway inhibitor (TFPI). Blood Coagul. & Fibrinolysis. 5:551-559.
13. Hamamoto, T., M. Yamamoto, O. Nordfang, J. G. L. Petersen, D. C. Foster, and W. Kisiel. 1993. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). J. Biol. Chem. 268:8704-8710.
14. Wesselschmidt, R., K. Likert, T. Girard, T.-C. Wun, and G. J. Broze, Jr. 1992. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of Factor Xa. Blood. 79:2004-2010.
15. Wesselschmidt, R., K. Likert, Z.-F. Huang, L. MacPhail, and G. J. Broze, Jr. 1993. Structural requirements for tissue factor pathway inhibitor interactions with Factor Xa and heparin. Blood Coagul. & Fibrinolysis. 4:661-669.
16. Nordfang, O., S. E. Bjorn, S. Valentin, L. S. Nielsen, P. Wildgoose, T. C. Beck, and U. Hedner. 1991. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 30:10371-10376.
17. Palmier, M. O., L. J. Hall, C. M. Reisch, M. K. Baldwin, A. G. E. Wilson, and T.-C. Wun. 1992. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb. Haemostasis. 68:33-36.
18. Bregengaard, C., O. Nordfang, P. Ostergaard, J. G. L. Petersen, G. Meyn, V. Diness, O. Svendsen, and U. Hedner. 1993. Pharmacokinetics of full-length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb. Haemostasis. 70:454-457.
19. Warshawsky, I., G. J. Broze, Jr., and A. L. Schwartz. 1994. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc. Natl. Acad. Sci. USA. 91:6664-6668.
20. Diaz-Collier, J. A., M. O. Palmier, K. K. Kretzmer, B. F. Bishop, R. G. Combs, M. G. Obukowicz, R. B. Frazier, G. S. Bild, W. D. Joy, S. R. Hill, et al. 1994. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb. Haemostasis. 71:339-346.
21. Warshawsky, I., G. Bu, and A. L. Schwartz. 1993. Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein. J. Biol. Chem. 268:22046-22054.
22. Bu, G., P. A. Morton, and A. L. Schwartz. 1992. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. J. Biol. Chem. 267:15595-15602.
23. 4. Nature (Lond.). 227:680-685.
24. Owensby, D. A., P. A. Morton, and A. L. Schwartz. 1989. Quantitative evaluation of receptor-mediated endocytosis. Methods Cell Biol. 32:305-328.
25. Novotny, W. F., M. Palmier, T.-C. Wun, G. J. Broze, Jr., and J. P. Miletich. 1991. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 78:394-400.
26. Creasey, A. A., A. C. K. Chang, L. Feigen, T.-C. Wun, F. B. Taylor, Jr., and L. B. Hinshaw. 1993. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91:2850-2860.
27. 4-4Gal-NAcβ1, 4GlcNAcβ1,2Manα. J. Biol. Chem. 267:19140-19146.
28. Wun, T.-C. 1992. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood. 79:430-438.
29. Sandset, P. M., U. Abildgaard, and M. L. Larsen. 1988. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res. 50:803-813.
30. Raychowdhury, R., J. L. Niles, R. T. McCluskey, and J. A. Smith. 1989. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science (Wash. DC). 244:1163-1165.
31. Kerjaschki, D., and M. G. Farquhar. 1983. Immunocytochemical localization of the Heymann nephritis antigen (gp330) in glomerular epithelial cells of normal Lewis rats. J. Exp. Med. 157:667-686.
32. Kerjaschki, D., A. Miettinen, and M. G. Farquhar. 1987. Initial events in the formation of immune deposits in passive Heymann nephritis. J. Exp. Med. 166:109-128.
33. Kounnas, M. Z., D. A. Chappell, D. K. Strickland, and W. S. Argraves. 1993. Glycoprotein 330, a member of the low density lipoprotein family, binds lipoprotein lipase in vitro. J. Biol. Chem. 268:14176-14181.
34. Moestrup, S. K., S. Nielsen, P. A. Andreasen, K. E. Jorgensen, A. Nykjaer, H. Roigaard, J. Gliemann, and E. I. Christensen. 1993. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J. Biol. Chem. 268:16564-16570.